Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now.

On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its common stock, priced at $6 per share. The offering also involved prepaid warrants to buy 833,333 shares at $5.999 per warrant.

Pixabay/Public domain

The company anticipates gross proceeds of around $200 million before accounting for underwriting commissions, discounts, and expenses, not including any underwriters’ option exercise. The company has granted the underwriters a 30-day option to buy up to an additional 5 million common shares.

On June 23, Bank of America Securities increased its target price on Taysha Gene Therapies Inc. (NASDAQ:TSHA) from $9 to $10, leading to an adjusted upside potential of more than 57%. The firm maintained a Buy rating on the stock following the company’s update regarding the Part A REVEAL study to evaluate TSHA-102 in Rett syndrome.

The firm stated the data supports the position of TSHA-102 as the earliest available disease-modifying treatment for Rett syndrome.

Taysha Gene Therapies Inc. (NASDAQ:TSHA) develops gene therapies that are based on adeno-associated virus. Its offerings include therapies such as TSHA-120, TSHA-102, TSHA-105, and others, aimed at the treatment of rare genetic diseases.

While we acknowledge the risk and potential of TSHA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TSHA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1